PP-018 Preparation of eye drops for vernal keratoconjunctivitis: the pharmacist added to a team acts as a fulcrum between doctor and patient

2015 ◽  
Vol 22 (Suppl 1) ◽  
pp. A123.3-A124
Author(s):  
V Borsi ◽  
C Sgromo ◽  
L Scala ◽  
G Scialino ◽  
A Calvani ◽  
...  
Keyword(s):  
Vernal Keratoconjunctivitis ◽  
Eye Drops

scholarly journals Tear Ferning Test and Pathological Effects on Ocular Surface before and after Topical Cyclosporine in Vernal Keratoconjunctivitis Patients

2018 ◽  
Vol 2018 ◽  
pp. 1-11
Author(s):  
Marcella Nebbioso ◽  
Marta Sacchetti ◽  
Guia Bianchi ◽  
Anna Maria Zicari ◽  
Marzia Duse ◽  
...  
Keyword(s):  
Cell Density ◽  
Goblet Cell ◽  
Ocular Surface ◽  
Goblet Cells ◽  
Significant Alteration ◽  
Vernal Keratoconjunctivitis ◽  
Eye Drops ◽  
Before And After ◽  
Tear Ferning Test ◽  
Goblet Cell Density

Background. Vernal keratoconjunctivitis (VKC) is a rare ocular surface inflammatory disease that affects mainly boys in the first decade of life. Clinical observations show that it generally regresses spontaneously with the onset of puberty, but therapeutic measures must be taken before then to control the course of the disease. Purpose.To evaluate the role of the lacrimal mucous component in VKC patients and compare tear ferning test (TFT) modifications, MUC5AC levels in tears, and density of conjunctival goblet cells to clinical characteristics before and after treatment with cyclosporine A (CY) in eye drops. Methods. Forty-seven patients affected by VKC and 30 healthy subjects aged between 3 and 16 years of life were enrolled. All individuals were submitted to complete eye examination and skin prick test (SPT) for the most common allergens. Then, they were subjected to collection of the tears and to impression cytology to evaluate TFT, MUC5AC levels, and conjunctival goblet cell density, before and after treatment with CY in eye drops. Results. Comparing the VKC group vs. the control group at baseline, a significant alteration in the degree of the ferns was found, indicating a pathological condition of the lacrimal mucous layer. In addition, an increased number of goblet cells were observed in the patients. The concentration of lacrimal secretory mucins (MUC5AC) did not show significant differences between the 2 groups. Patients treated with CY have reported improvements of some signs and symptoms of disease activity, including TFT, and a tendency of conjunctival goblet cell density to normalise. Conclusions. The results obtained demonstrated for the first time a significant alteration of the lacrimal mucin component evaluated in the VKC group, and an improvement of the latter after CY therapy.

Therapeutic Effect of 0.1% Tacrolimus Eye Drops in the Tarsal Form of Vernal Keratoconjunctivitis

2017 ◽  
Vol 59 (3) ◽  
pp. 126-134 ◽  
Author(s):  
Qi Wan ◽  
Jing Tang ◽  
Yu Han ◽  
Dan Wang ◽  
Hongquan Ye
Keyword(s):  
Therapeutic Effect ◽  
Vernal Keratoconjunctivitis ◽  
Eye Drops

scholarly journals COMPARATIVE EVALUATION OF TACROLIMUS 0.03% OINTMENT VS OLOPATADINE 0.2% EYE DROPS IN THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS

2021 ◽  
Vol 71 (1) ◽  
pp. 34-39
Author(s):  
Hassan Sajjad Rathore ◽  
Shahzad Saeed ◽  
Ahsan Mukhtar ◽  
Umar Ijaz ◽  
Asad Habib ◽  
...  
Keyword(s):  
Subjective Symptom ◽  
Military Hospital ◽  
Vernal Keratoconjunctivitis ◽  
Eye Drops ◽  
Subjective Symptoms ◽  
Cross Sectional ◽  
Group A ◽  
Objective Sign ◽  
The Mean ◽  
Group B

Objective: To compare the efficacy of tacrolimus 0.03% ointment to olopatadine 0.2% eye drops in the treatment of vernal keratoconjunctivitis. Study Design: Prospective cross-sectional study. Place and Duration of Study: Eye Department Combined Military Hospital Quetta, from Feb to Jul 2019. Methodology: A total of 69 patients with active vernal keratoconjunctivitis (VKC) were included in this study.Thirty six (52.17%) patients were randomized in tacrolimus group and 33 (47.83%) in olopatadine group B.Baseline values of the subjective symptom score (SSS) and the objective sign score (OSS) were noted. Patientswere reviewed on weeks 2, 4, 8 and 12 and the scores at each visit were summed. These scores were used forcomparison between groups. Results: At the start of the study, the mean subjective symptoms score and objective sign score of group A was 9.0 ± 2.04 and 3.93 ± 1.93 respectively, while that of group B was 8.88 ± 2.18 and 4.36 ± 1.90 respectively. At the end of 12-weeks, the mean subjective symptoms score and objective sign score of group A reduced to 0.11 ± 0.32 and 0.08 ± 0.28 respectively, while that of group B reduced to 1.70 ± 0.77 and 0.64 ± 0.55 respectively. Total improvement of scores (as a percentage of baselines) among tacrolimus group was 98.3% and olopatadine group was 83%. Conclusion: Although both 0.03% tacrolimus and 0.2% olopatadine were effective in improving the signs andsymptoms of VKC, 0.03% tacrolimus was significantly superior.

Eyelash Length in Children with Vernal Keratoconjunctivitis: Effect of Treatment with Cyclosporine Eye Drops

2007 ◽  
Vol 20 (3) ◽  
pp. 595-599 ◽  
Author(s):  
N. Pucci ◽  
C. Massai ◽  
R. Bernardini ◽  
R. Caputo ◽  
F. Mori ◽  
...  
Keyword(s):  
Rapid Change ◽  
Ocular Inflammation ◽  
Vernal Keratoconjunctivitis ◽  
Eye Drops ◽  
Rapid Improvement ◽  
Humoral Factors ◽  
Significant Difference ◽  
Group 3 ◽  
Group 2 ◽  
Group 1

The upper eyelashes in vernal keratoconjunctivitis (VKC) patients have been reported to be longer than in healthy age- and gender-matched subjects. Eyelash length positively correlated to the severity of the disease and negatively to the employment of cyclosporine eye drops, suggesting that specific humoral factors could be involved in both ocular inflammation and elongation of the eyelashes. The aim of the present study is to evaluate a possible relationship between eyelash length and the duration of topical cyclosporine treatment. The length of the upper eyelashes of 34 VKC patients never treated with topical cyclosporine (Cyc-NT) was matched with that of 58 VKC patients treated with cyclosporine (Cyc-T). The latter group was divided into three subgroups, depending on the duration of therapy: 1–6 months (group 1; 21 subjects), 7–12 months (group 2; 19 subjects), >12 months (group 3; 19 subjects). Cyc-NT patients' eyelashes were significantly longer than those of VKC patients treated for 1–6 months (group 1). No significant difference was found between Cyc-NT and Cyc-T patients in group 2 and group 3. The differences between Cyc-T patients and group 1 and 2, group 2 and 3, and group 1 and 3 were not statistically significant. The eyelash shortening observed seems directly related to the rapid improvement of ocular symptoms induced by the treatment. A receptor down-regulation by mediators of ocular inflammation may explain this data, although different cytokines, hormones or other humoral mediators could be expressed on the ocular surface at different stages of the disease, mainly in periods of rapid change of the clinical course.

scholarly journals Tacrolimus eye drops as monotherapy for vernal keratoconjunctivitis: a randomized controlled trial

2017 ◽  
Vol 80 (3) ◽  
Author(s):  
Eduardo Gayger Müller ◽  
Myrna Serapião dos Santos ◽  
Denise Freitas ◽  
José Álvaro Pereira Gomes ◽  
Rubens Belfort Jr.
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Vernal Keratoconjunctivitis ◽  
Eye Drops ◽  
Randomized Controlled

scholarly journals Vitamin D serum levels in children with vernal keratoconjunctivitis and disease control

2019 ◽  
Vol 33 ◽  
pp. 205873841983346
Author(s):  
Daniele Giovanni Ghiglioni ◽  
Gaia Bruschi ◽  
Sara Gandini ◽  
Silvia Osnaghi ◽  
Diego Peroni ◽  
...  
Keyword(s):  
Vitamin D ◽  
Steroid Therapy ◽  
Sun Exposure ◽  
Serum Levels ◽  
Vernal Keratoconjunctivitis ◽  
Eye Drops ◽  
Overweight Children ◽  
Ocular Symptoms ◽  
Significant Difference ◽  
Pre Treatment

The aim of this study was to evaluate whether the control of ocular symptoms with cyclosporine or with tacrolimus in eye drops allows to improve sun exposure and therefore serum level of vitamin D (VD; 25OHD), in the more severe forms of vernal keratoconjunctivitis (VKC). Out of 242 children followed for active VKC, 94 were treated with 1% cyclosporine or 0.1% tacrolimus eye drops, while the other 148 with mild VKC did not need to be treated with immunomodulators. VD serum levels were measured in spring and autumn in 71 children. In total, 60 of them were treated with cyclosporine eye drops (first group) and 11 (not responding to cyclosporine therapy previously) with 0.1% tacrolimus eye drops (second group) between March and November 2016. Pre-treatment median values of VD were 23.7 ng/mL in the first group and 23.8 in the second group, and post-treatment values increased up to 32.8 and 32.9 ng/mL, respectively. Before treatment, 33% presented a deficiency (25OHD < 20 ng/mL), and at the end of summer, only 4% were deficient. The overweight children had lower improvement in VD serum levels than children with a body mass index (BMI) lower than 85th percentile. Children in therapy with cyclosporine, but requiring the administration of local steroid therapy during the summer for control of the symptoms, showed a greater improvement in 25OHD serum levels in ng/mL (23–37 ng/mL) than children who did not require steroid therapy (24–35 ng/mL). Furthermore, there was a significant difference in change of 25OHD in children presenting limbal VKC (21–41 ng/mL) versus tarsal VKC (24–35 ng/mL) ( P = 0.04). Our study suggests that ocular treatment carried out with immunomodulator eye drops could allow for an improvement in 25OHD serum levels. In children with active VKC and at risk of 25OHD deficiency, likely due to avoidance of sun exposure, the role of other risk factors (BMI, phototype and treatment) on 25OHD serum levels should be considered.

Sign in / Sign up

Export Citation Format

Share Document